Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome

被引:23
|
作者
Katsumata, Ryo
Shiotani, Akiko
Murao, Takahisa
Ishii, Manabu
Fujita, Minoru
Matsumoto, Hiroshi
Haruma, Ken
机构
[1] Division of Gastroenterology, Department of Internal medicine, Kawasaki Medical School
[2] Department of General Internal medicine 2, Kawasaki Medical School
关键词
irritable bowel syndrome; serotonin; serotonin transporter; tryptophan hydroxylase; S100; A10; S100; PROTEINS; INTESTINAL INFLAMMATION; FECAL CALPROTECTIN; ULCERATIVE-COLITIS; ABDOMINAL-PAIN; EXPRESSION; SYMPTOMS; TRANSPORTER; ACTIVATION; MOTILITY;
D O I
10.2169/internalmedicine.56.7674
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Gender differences, including differences in the prevalence, subtypes and the effectiveness of treatment, are generally recognized in irritable bowel syndrome (IBS). Although serotonin type 3 receptor (5-HT3R) antagonists appear to be more effective in women with diarrhea predominant IBS (IBS-D) than they are in men, the mechanisms underlying these effects remain unclear. The aim of the present was to investigate the gender differences in 5-HT signaling. Methods The subjects were selected from outpatients with IBS-D and healthy controls. Their rectal mucosal S100A, tryptophan hydroxylase (TPH) and 5-HT transporter (5-HTT, SERT, SLC6A4) mRNA expression levels were measured. Clinical symptoms were evaluated using the gastrointestinal symptom rating scale (GSRS) and the self-rating depression scale (SDS). Results The study population of 100 subjects included 47 IBS-D patients and 53 age-and gender-matched healthy controls. The S100A9 (5.20 vs. 1.90, p=0.001) and SLC6A4 (2.00 vs. 1.00, p=0.019) mRNA levels in the rectal mucosa of women with IBS-D were significantly higher than those in men. Among the healthy controls, the S100A10 expression levels in men were higher than those in women (1.33 vs. 0.82, p=0.005). The S100A8 and S100A10 expression levels in women with IBS-D were positively correlated with their diarrhea scores (r=0.55 and 0.58, p<0.05). Conclusion 5-HT signaling might be a major contributor to the symptoms of IBS in men, and the differences may be associated with the effectiveness of 5-HT3R antagonists.
引用
收藏
页码:993 / 999
页数:7
相关论文
共 50 条
  • [1] Gender differences in placebo response in patients with diarrhea-predominant irritable bowel syndrome (D-IBS)
    Ameen, VZ
    Heath, AT
    Chang, L
    GASTROENTEROLOGY, 2005, 128 (04) : A463 - A463
  • [2] Rifaximin in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
    Dai, Cong
    Jiang, Min
    Sun, Ming-Jun
    GASTROENTEROLOGY, 2017, 152 (06) : 1629 - +
  • [3] Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome
    Camilleri, M
    Atanasova, E
    Carlson, PJ
    Ahmad, U
    Kim, HJ
    Viramontes, BE
    McKinzie, S
    Urrutia, R
    GASTROENTEROLOGY, 2002, 123 (02) : 425 - 432
  • [4] IRRITABLE BOWEL SYNDROME - PHYSIOLOGICAL AND PSYCHOLOGICAL DIFFERENCES BETWEEN DIARRHEA-PREDOMINANT AND CONSTIPATION-PREDOMINANT PATIENTS
    WHITEHEAD, WE
    ENGEL, BT
    SCHUSTER, MM
    DIGESTIVE DISEASES AND SCIENCES, 1980, 25 (06) : 404 - 413
  • [5] Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
    Lacy, Brian E.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2016, 9 : 7 - 17
  • [6] Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome
    Kane, John S.
    Ford, Alexander C.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (04) : 431 - 442
  • [7] The intestinal microbiome of diarrhea-predominant irritable bowel syndrome
    Carroll, I. M.
    Ringel-Kulka, T.
    Siddle, J. P.
    Ringel, Y.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 23 : 13 - 13
  • [8] Role of Diet in Diarrhea-predominant Irritable Bowel Syndrome
    Singh, Prashant
    Nee, Judy
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (01) : 25 - 29
  • [9] Targeted therapies for diarrhea-predominant irritable bowel syndrome
    Olden, Kevin W.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2012, 5 : 69 - 100
  • [10] Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
    Ozdener, Ayse Elif
    Rivkin, Anastasia
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2827 - 2840